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ABSTRACT
Reduced-intensity conditioning regimens for transplant recipients have heightened awareness of immunologic
resistance to allogeneic bone marrow transplants (BMT). Although T cell–mediated cytotoxicity has been
assumed to play a role in the resistance against donor allogeneic hematopoietic stem and progenitor cell grafts,
several studies have reported relatively unimpaired resistance by recipients who lack perforin, Fas ligand
(FasL), and other cytotoxic mediators. This study compared the early kinetics of T cell–mediated resistance in
B6 (H2b) cytotoxically normal versus deficient recipients after transplantation with major histocompatibility
complex–matched, minor histocompatibility antigen (MiHA)–mismatched allogeneic marrow grafts. Wild-type
B6 or cytotoxic double-deficient perforin//gld/ (B6-cdd) mice were sensitized against major histocom-
patibility complex–matched BALB.B or C3H.SW (H2b) MiHA and transplanted with a high dose (1  107) of
T cell–depleted bone marrow. CD8 T memory cells were shown to be present in recipients before BMT, and
anti-CD8 monoclonal antibody infusion abolished resistance, thus demonstrating that CD8 T cells are the host
effector population. Donor-committed and high proliferative potential progenitor numbers were markedly
diminished by 48 hours after transplantation in both wild-type B6 and B6-cdd anti–donor MiHA–sensitized
recipients. These observations indicate that the resistance pathway used in the cytotoxic deficient mice was
both potent and rapidly induced—consistent with a CD8 memory T-cell response. To examine the role of
Tumor necrosis factor–like weak inducer of apoptosis (TWEAK)- and TL1A-mediated cytotoxicity in this
strong resistance, newly generated monoclonal antibodies specific for these ligands were administered to
B6-cdd recipients sensitized to donor antigens. Recipients of syngeneic B6-gfp bone marrow exhibited
significant donor colony-forming unit numbers after BMT. In contrast, low or absent colony-forming unit
levels were detected in allogeneic recipients, including those that lacked perforin and FasL and that received
anti-TWEAK, anti–tumor necrosis factor–related apoptosis-inducing ligand, and anti-TL1A monoclonal an-
tibodies. These findings extend previous observations by demonstrating the existence of a rapidly effected
resistance pathway mediated by memory CD8 effector T cells independent of the 2 major pathways of
cytotoxicity. Together with previous findings, these results support the notion that effector cells derived from
memory CD8 T-cell populations can mediate strong resistance against donor allogeneic MiHA-disparate
hematopoietic engraftment by using a mechanism that is independent of the contribution of perforin, FasL, and
the known death ligand receptor pathways.
© 2005 American Society for Blood and Marrow Transplantation
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bNTRODUCTION
Bone marrow transplantation (BMT) is an impor-
ant therapeutic modality for the treatment of many
ematopoietic malignancies and other disorders.
raft failure due to immunologic resistance against
onor allogeneic bone marrow (BM) grafts by the
ecipient is a major concern in clinical transplantation.
his is especially relevant to protocols that involve
raft T-cell depletion or nonmyeloablative recipient
onditioning [1-3]. It is well established that both
-cell and natural killer (NK) cell subsets can con-
ribute to the host antigraft barrier that must be over-
ome to achieve successful donor engraftment [4-6].
he contribution of individual cellular subsets can
iffer depending on transplantation parameters such
s the genetic disparity between donor and recipient
nd the status of host antidonor reactivity. For exam-
le, the presence of alloantigen-sensitized T cells in
ndividuals who have previously undergone a trans-
lantation or in patients with aplastic anemia who can
ecome sensitized to alloantigens via blood transfu-
ions before transplantation is associated with higher
evels of graft resistance and engraftment failure [1,7].
nvestigation of the molecular mediators used by spe-
iﬁc host-resisting cell populations is important to
evelop strategies to disrupt the rejection process
hile allowing for graft-versus-tumor activity.
We and others have previously studied the contri-
ution of cytotoxic pathways to T cell–mediated re-
istance against donor progenitor/stem cells in a do-
or alloantigen–sensitized experimental model [8-10].
onor antigen–sensitized recipient mice deﬁcient in
oth perforin and Fas ligand (FasL) function (B6-cdd)
aintain strong resistance to major histocompatibility
omplex (MHC)–mismatched (BALB/c: H2d) and
HC-matched/minor histocompatibility antigen
MiHA)–mismatched (C3H.SW or BALB.B: H2b)
M. Both T cells and antibody could contribute to
esistance in the former; however, resistance in the
atter can be transferred by CD8 T cells and was
hown to be equally effective against tumor necrosis
actor (TNF)–receptor 1 (p55)–deﬁcient and TNF-
eceptor 2 (p75)–deﬁcient progenitors [8,10]. Fur-
hermore, resistance is not diminished by the intro-
uction of blocking antibody to the apoptosis-
nducing TNF family member TNF-related
poptosis-inducing ligand (TRAIL), which mediates
ignaling via death receptor (DR)4/DR5 [10].
This investigation examined the early kinetics of
esistance in donor antigen–sensitized B6-cdd and
ild-type B6 (B6-wt) recipients after transplantation
f MiHA-disparate BM cells (BMCs). By using R
B&MTALB.B donors in this study, antigen-speciﬁc CD8
emory T cells (TM) cells against the immunodomi-
ant H60 minor transplantation antigen were identi-
ed in recipients before transplantation [11]. Findings
emonstrate that resistance against progenitor cells in
hese recipients is an effective and rapidly occurring
vent mediated by host CD8 T cells whether or not
he major cytotoxic pathways are functional in trans-
lant recipients. We further investigated the operative
olecular pathway of this TM-dependent resistance.
nvolvement of 2 additional TNF family ligands ca-
able of inducing apoptosis has not been previously
xamined in allograft resistance. Tumor necrosis fac-
or–like weak inducer of apoptosis (TWEAK) and
L1A have both been shown to be expressed on
ctivated T cells [12,13]. TWEAK has been shown to
e capable of weakly inducing apoptosis upon binding
ts receptor Fn14, whereas TL1A binds DR3, 1 of a
amily of receptors that contains a cytoplasmic cys-
eine-rich protein interaction motif termed the death
omain, which is capable of recruitment and activation
f procaspase 8 and initiation of cell death [14]. To-
ether with deﬁciencies in perforin and FasL, recently
roduced monoclonal antibodies (mAbs) were used
nd shown to block apoptotic signaling through Fn14,
R3, and DR5 individually and in combination to
isrupt 3 additional cytotoxic pathways in transplan-
ation models. The simultaneous disruption of 5 sig-
aling pathways did not alter the strong resistance
ediated by cytotoxically defective antigen-sensitized
ecipient mice. Together with our previous ﬁndings,
hese observations are consistent with the notion that
f the killing of donor progenitor cells occurs during
esistance responses, at least 1 cytotoxic pathway dis-
inct from TWEAK, TL1A, TRAIL, FasL, perforin,
nd TNF is operative and effective in mediating
trong resistance by CD8 TM against MiHA-mis-
atched BM progenitor/stem cell allografts. These
ndings support further investigation to address the
recise role of apoptosis and cellular cytotoxicity in
llogeneic stem/progenitor cell rejection.
ATERIALS AND METHODS
ice
C57BL/6J (B6, H2b), C3H.SW (H2b), B6.Smn
3H-gld (B6-gld/gld, H2b), and BALB.B (H2b) mice
ere initially obtained from the Jackson Laboratories
Bar Harbor, ME). C57BL/6 Cr Slc TgN(act-EGF-
)OsbC15-001-FJ001 (B6-gfp) mice were provided
y Dr. M. Okabe (Program for Promotion of Basic
esearch Activities for Innovative Biosciences, Osaka
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5niversity, Suita, Japan). Mice 8 to 16 weeks of age
ere sex-matched for transplantations involving only
ormal, ie, wild-type, mice. B6-perforin/ (H2b)
ice were maintained in pathogen-free conditions at
he University of Miami School of Medicine. B6 cy-
otoxic double-deﬁcient (perforin and FasL) mice (B6-
dd) were generated from B6 Pfp/ Faslgld/gld pairings
r B6 Pfp/ Faslgld/gld B6 Pfp/ Faslgld/gld pairings,
s previously described [15]. Each offspring was care-
ully screened for homozygosity for perforin deﬁ-
iency. Brieﬂy, genomic DNA was isolated from the
ails of each offspring to be transplanted by using a
Neasy Tissue Kit (Qiagen, Hilden, Germany).
hree primers (PKO1, 5=-CAGGTCAGGCCAG-
ATAAGAGTAG-3=; PKO2, 5=-AAGGTCAT-
ATCCCAGCCGTAGTC-3=; and PKO3, 5=-AGC-
GGATCAAGCGTATGCAG-3=) were used to
mplify wild-type and disrupted perforin genes from
enomic DNA. PKO1 and PKO2 primers were 5= and
= primers speciﬁc to the mouse perforin sequence,
espectively. The PKO3 primer sequence is contained
ithin the neomycin cassette that disrupts synthesis of
unctional perforin messenger RNA. Mice were
creened as previously described [9,16].
B6-cdd mice develop spontaneous cdd syndrome,
hich results in early death by 15 weeks [15]. There-
ore, all B6-cdd mice underwent transplantation be-
ween 49 and 56 days (7-8 weeks) of age. B6-FasLgld/gld
ice do not exhibit such early death; therefore, the
6-cdd phenotype is also monitored by the life span of
enotyped mice not used as BMT donors. The colony
ife span is 97.1  9.8 days, which is consistent with
ublished results.
ell Lines
The mouse B-cell lymphoma 2PK3 and L929 cell
ines were obtained from the American Type Culture
ollection (Manassas, VA). 2PK3/mTRAIL was gen-
rated as previously described and routinely carried in
ur laboratories [17].
riming against MiHA Alloantigens
Single-cell suspensions were prepared from
pleen, lymph node, and thymus tissue of C3H.SW or
ALB.B mice. Cells were adjusted to a concentration
f 5  107/mL, and 0.5 mL was administered by
ntraperitoneal injection 4 weeks before BMT where
ndicated.
dentification of Host Anti–Donor-Specific
D8 TM
To determine the frequency of anti–donor anti-
en–speciﬁc host CD8 T cells expressing the mem-
ry phenotype, peripheral blood was obtained from
6 mice primed with BALB.B cells, depleted of red
lood cells, and stained with the tetramer H2Kb- w
78TFNYRNLT H60 conjugated to phycoerythrin
National Institutes of Health Tetramer Facility, At-
anta, GA). Aliquots of cells were costained with anti–
D8-cychrome (BD Biosciences, San Diego, CA),
nd either CD44 (BD Biosciences) or Ly6C (BD Bio-
ciences) was conjugated to ﬂuorescein isothiocyanate.
ated CD8H60 cells were then analyzed for ex-
ression of CD44 and Ly6C.
one Marrow Transplantation
MHC-matched/MiHA-mismatched BALB.B (H2b)
nd C3H.SW (H2b) BMCs were transplanted into
6-wt and B6-cdd recipients. Femurs and tibiae were
arvested from appropriate female donors. T cells were
emoved by incubation with anti-Thy1.2 mAb (HO13.4
scites diluted 1:200) followed by 10% vol/vol Low-Tox
rabbit complement (Accurate Chemical & Scientiﬁc
orp., Westbury, NY) at 37°C for 45 minutes. T cells
resent were reduced from approximately 2.0% to below
he level of detection (ie, 0.2%) by ﬂuorescence-acti-
ated cell sorting. Recipient mice received 9.0 Gy of
ethal total body irradiation from an open-beam cobalt
0 gamma (50 cGy/min) source. Twenty-four hours
ater, 1  107 T cell–depleted (TCD) BMCs were in-
used intravenously into recipient mice that were main-
ained on acidiﬁed water (pH 2.2).
olony-Forming Unit Assay
Recipients were killed 5 days after BMT. Pooled
plenocytes (1  105) were cultured in 1 mL of a
ixture containing Dulbecco’s modiﬁed Eagle me-
ium, 0.86% methyl cellulose (Methocult; StemCell
echnologies, Vancouver, BC, Canada), 30% fetal
alf serum, 250 mol/L 2-mercaptoethanol, 2
mol/L l-glutamine, 100 U/mL penicillin, 100
g/mL streptomycin, and 50 U/mL interleukin
IL)–3 (R&D Systems, Inc., Minneapolis, MN) for
olony-forming unit (CFU)–IL-3 or 100 ng/mL stem
ell factor (PeproTech, Rocky Hill, NJ), 50 U/mL
L-3, and 2700 U/mL IL-1 (PeproTech) for CFU-
igh proliferative potential (HPP). Triplicate cultures
ere maintained at 37°C in 5% carbon dioxide for 5
ays (CFU–IL-3) or 7 to 14 days (CFU-HPP). Cell
ggregates containing 25 cells were scored as indi-
idual CFU–IL-3 colonies. Results are presented as
verage CFU–IL-3 and CFU-HPP  SD per group.
eneration of Anti-mTL1A mAbs
The extracellular region of mTL1A was fused to
he amino-terminal maltose-binding protein (MBP)
nd the neck region of human surfactant in the
MAL-c2x vector (New England Biolabs, Beverly,
A). The protein was expressed in JM109 and puri-
ed from bacterial lysate by using amylose resin. Ar-
enian hamsters were immunized 3 times every 2
eeks with 50 g of MBP-mTL1A in Freunds ad-
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Effector Cells Derived from Host CD8 Memory T Cells
Buvant intraperitoneally. Three days before the fusion,
hey were boosted with 50 g of protein intrave-
ously. Splenocytes from immunized animals were
solated, fused with SP2/0 myeloma, and cloned by
sing a ClonaCell-HY hybridoma kit (StemCell
echnologies). Supernatants from individual clones
ere tested by enzyme-linked immunosorbent assay
ith MBP-mTLA–coated plates and peroxidase-con-
ugated goat anti-hamster immunoglobulin (Ig)G
Jackson Immunoresearch Labs, Bar Harbor, ME).
wo positive clones, L3A10 and L4G6, were ex-
anded into a serum-free medium, and antibodies
ere puriﬁed on a protein G column.
ntibody Treatment of BMT Recipients
The mAbs anti-TRAIL (N2B2, rat IgG2a), anti-
WEAK (MTW-1, rat IgG1; generated as previously
escribed) [17,18], and anti-TL1A were administered
ia intraperitoneal injection (250 g per injection) on
ay 0 in the morning before BMT and again on day
1 after BMT. Host CD8 T cells were depleted by
sing rat anti-mouse 2.43 (anti-CD8 mAb) adminis-
ered on days 7, 5, and 3 (100 g per mouse).
epletion was assessed by staining host peripheral
lood mononuclear cells (PBMCs) and spleen cells by
sing clone 53-6.7 (ﬂuorescein isothiocyanate la-
eled). Cells that stained 0.01% were identiﬁed in
BMCs before transplantation (day1), and recipient
pleen cells were identiﬁed after transplantation (day
5), thus conﬁrming effective depletion, as previously
eported [19].
n Vitro Cytotoxicity Assays
Experiments examining TRAIL-mediated killing
ere performed by using 2PK3/mTRAIL or control
ontransfected 2PK3 effector cells incubated with
hromium 51 (51Cr)–labeled L929 cells (L929 has
een previously demonstrated to be susceptible to
RAIL-mediated lysis) [17] at varying effector-target
atios for 4 hours. Anti-TRAIL mAb or an isotype
ontrol antibody was added to cultures where indi-
ated at a concentration of 10 g/mL. After incuba-
ion, supernatants were harvested and counted on a
amma counter. Speciﬁc killing (percentage of cyto-
oxicity) was calculated as follows: [(experimental re-
ease  spontaneous release) M/(maximal release 
pontaneous release)] &times 100. The percentage of
peciﬁc lysis is indicated as a mean of triplicate cul-
ures at each effector-target ratio.
To demonstrate the blocking properties of anti-
L1A mAb ex vivo, a source of TL1A and DR3 target
ells was required. The mTL1A and mDR3 were
btained by reverse transcription-polymerase chain
eaction from concanavalin A–stimulated BL/6
plenocytes, cloned in a modiﬁed expression vector
pBMG-Neo), and introduced into EL4 cells by elec- r
B&MTroporation. Positive clones were selected with G418
nd assessed for DR3 expression with 4C12 Armenian
amster anti-mDR3 antibody (generated in our labo-
atory; V.D. and E.P.) and for TL1A expression with
he L4G6 and L3A10 antibodies described previously
data not shown). Standard 4-hour 51Cr release assays
sing EL4 cells transfected with full-length DR3 as
argets were then performed. The supernatant of
TL1A-transfected EL4 cells was used as a source of
igand, ie, TL1A. Serial dilutions of mTL1A superna-
ant (75 L) were mixed with 75 L of hybridoma
upernatants (discussed previously), incubated for 30
inutes, and added to 1 104 51Cr-labeled EL4-DR3
ells. After 4 hours of incubation, supernatants were
arvested and counted, and speciﬁc killing was calcu-
ated as described previously.
tatistics
For each experiment, BMCs were harvested from
minimum of 2 donor mice, pooled, and transplanted
nto a minimum of 3 recipient mice for every experi-
ental group. CFU values are presented as an average
f triplicate wells with standard deviations. For assays
xamining the levels of CFU–IL-3 and CFU-HPP
nd in vivo anti-CD8 mAb inhibition, statistical sig-
iﬁcance between groups was examined by 1-way
nalysis of variance with the Tukey post hoc test,
eported as P values where appropriate [20].
ESULTS
dentification of Host Anti–Donor
ntigen–Specific TM in Donor Antigen–Sensitized
ecipients before Rapid CD8 T Cell–Mediated
esistance against MiHA-Mismatched
arrow Allografts
We have previously reported that progenitor cell
llograft resistance in antigen-sensitized recipients is
n efﬁcient and antigen-speciﬁc event and that such
esistance against MiHA-mismatched donor allografts
an be transferred from mice sensitized against donor
ntigens [9,10]. Adoptive transfer of populations en-
iched in CD8 T cells from such mice into naive
yngeneic recipients resulted in resistance against the
ppropriate donor marrow cells [10]. To deﬁnitively
ocument that CD8 T cells were the effector popu-
ation in sensitized recipients after conditioning and
MT of MHC-matched/MiHA-mismatched marrow
rafts, C3H.SW recipients primed against B6 MiHA
designated B6C3H.SW) were infused with anti-CD8
Ab (2.43) during the week before transplantation
ith 1  107 B6-TCD BMCs. The failure to identify
D8 T cells in these mice before (PBMCs) and after
spleen) transplantation conﬁrmed CD8 T-cell deple-
ion (data not shown). Control recipients vigorously
esisted the donor marrow, as evidenced by the ab-
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5ence of committed (CFU–IL-3) and more primitive
CFU-HPP) progenitors in recipient spleen cells 5
ays after BMT (Figure 1). However, spleen cells
rom recipients treated with anti-CD8 mAb contained
onor CFU–IL-3 and CFU-HPP at levels indistin-
uishable from those in control recipients (Figure 1).
high dose (1  107) of BALB.B (H2b) or BALB/c
H2d) TCD BM was transplanted into B6 recipients
rimed to BALB.B MiHA to override NK resistance
data not shown). BALB.B, but not BALB/c, marrow
as resisted, consistent with MHC-restricted CD8 T
ell–mediated resistance, thus further corroborating
esults from mixed transplant experiments [9]. These
ndings together with previous results demonstrate
hat host radioresistant CD8 T cells in mice sensitized
gainst donor antigens are responsible for the speciﬁc
esistance against MiHA-disparate donor marrow
9,10].
After sensitization against donor MiHA, TM pop-
lations would be predicted to be present in recipients
efore receipt of marrow allografts. To examine the
resence of anti–donor antigen–speciﬁc CD8 TM in
uch mice, B6 recipients were primed against BALB.B
ntigens, which include the immunodominant H60
iHA [11,21,22]. By using a tetramer speciﬁc for the
6 T-cell receptor (see “Materials and Methods”),
60 CD8 T cells were readily detected in recipients
ensitized to BALB-encoded MiHA (Figure 2), con-
istent with prior observations [11]. These tetramer-
ositive cells exhibited CD44hiLy6Chi expression, a
henotype characterizing CD8 TM [23]. Such sensi-
ized recipients efﬁciently resisted donor marrow al-
ografts (Figure 2).
Previously we have reported that B6-wt and B6-
igure 1. B6-wt (H2b) recipients were sensitized to C3H.SW (H
ethods”) to deplete host CD8 T cells before transplantation. Co
ody irradiation, B6-wt recipients underwent transplantation with 1
ransplantation as controls. At 5 days after transplantation, recipient
CFU-GM) (A) or CFU-HPP (B). Data represent CFUs per spleen
y analysis of variance with the Tukey multiple comparison test.dd recipients primed to donor MiHA showed equiv- m
80lent resistance after a 2  106 TCD BM allograft as
ssessed at 5 days after transplantation [10]. To more
ensitively analyze the resistance in these 2 strains, a
igh dose of C3H.SW BM (1  107 BMCs) was
ransplanted into B6-wt and B6-cdd recipients sensi-
ized to C3H MiHA, and resistance was examined 48
ours after transplantation. Resistance was detected in
ensitized B6-wt recipients at this early time after
ransplantation as evidenced by signiﬁcantly dimin-
shed numbers of committed and pluripotential
plenic CFUs compared with the numbers present at
his time in naive recipients (Figure 3). Because some
FUs were detectable in these B6-wt recipients, this
ose of BM represented a sensitive number of cells to
ransplant with which to compare the resistance in
6-cdd recipients. Identiﬁcation of more colonies in
6-cdd recipients would support the interpretation of
eaker resistance, and fewer CFUs would support the
nterpretation of stronger resistance compared with
6-wt. However, efﬁcient resistance, which was indis-
inguishable (P  .05), was detected in the B6-cdd
ersus B6-wt recipients. These ﬁndings indicate that
n sensitized recipients containing CD8 TM, the ef-
ector pathways used by resisting host T cells in the
bsence of perforin and FasL are also rapidly activated
nd highly efﬁcient in the early posttransplantation
eriod.
he Apoptosis-Inducing Ligand TWEAK Is Not
nvolved in Resistance Against Allogeneic Marrow
rafts by Antigen-Sensitized Host CD8 T Cells
To investigate the involvement of TWEAK-in-
uced cytotoxicity in TM-mediated resistance against
HC-matched/MiHA-mismatched BM, B6-cdd
loantigens and administered anti-CD8 mAb (see “Materials and
were treated with phosphate-buffered saline. After 9.0 Gy of total
C3H.SW TCD BM cells. Unsensitized recipients also underwent
ytes were harvested and assayed for CFU-granulocyte macrophage
 SEM). Statistical differences between groups were determined2b) al
ntrols
 107
splenoc
(meanice were primed against C3H.SW (H2b) donors.
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Effector Cells Derived from Host CD8 Memory T Cells
Bour weeks after priming, mice were lethally condi-
ioned (9.0 Gy) and underwent transplantation with
3H.SW BM-TCD (1  107). On day 0 (before
ransplantation) and day 1 after transplantation,
ice received an intraperitoneal injection of large
mounts (250 g) of anti-TRAIL (N2B2) and anti-
WEAK (MTW-1) mAbs. B6-cdd mice have been
reviously shown to resist MiHA-disparate marrow
rafts [14]. Five days after transplantation, recipient
plenocytes were harvested and plated with appropri-
te growth factors to assess for CFU–IL-3 (Figure 4A)
nd CFU-HPP (Figure 4B). Recipient mice sensitized
gainst donor antigens and transplanted with alloge-
eic BM demonstrated strong resistance even in the
resence of mAbs speciﬁc for TRAIL or TWEAK.
he presence of low CFU numbers in these resisting
ice supports the likelihood that inhibition of resis-
ance by these antibodies would have been detected by
ncreased numbers. In contrast, mice that received
yngeneic B6-gfp marrow demonstrated substantial
FU activity, and all colonies were gfp by ﬂuores-
ence microscopy (data not shown), thus indicating
onor origin (Figure 4A and B). The blocking activity
f the anti-TRAIL (Figure 4C) and anti-TWEAK
igure 2. A, Immunodominant (H60) MiHA-speciﬁc CD8 cells ex
ALB.B cells intraperitoneally and 4 weeks later were boosted with 2
nalyzed for the presence of tetramer staining (H60 phycoerythr
ismatched donor marrow grafts in B6BALB.B recipients. B6-wt mice
ody irradiation (day1) and then underwent transplantation with 1
ssays were performed. Data are expressed as percentage of controAbs used was veriﬁed in vitro as previously described d
B&MT17,18], and the doses were sufﬁcient to block TRAIL-
r TWEAK-mediated tumor rejection in vivo (data
ot shown). Anti-TRAIL mAb was shown to effec-
ively block in vitro TRAIL-mediated lysis by effector
ells against L929 targets (Figure 4C). The N2B2
Ab has also been shown to increase metastatic car-
inoma lesions during a 2-week time period in B6
ice [24]. In summary, mice that effect CD8 T
ell–mediated resistance strongly inhibit the MHC-
atched/MiHA-disparate donor CFU presence in the
imultaneous absence of TWEAK, TRAIL, FasL, and
erforin-mediated cytotoxicity.
nhibition of the TL1A-DR3 Pathway Does Not
iminish Resistance in Donor Antigen–Primed
ecipients against BM Allografts
TL1A/DR3-dependent BM graft resistance by T
ells has not been previously investigated. To examine
ny involvement of this ligand-receptor interaction in
he rejection of MHC-matched/MiHA-mismatched
ematopoietic progenitors, blocking and control
nonblocking) mAbs recently generated against TL1A
see “Materials and Methods”) were used. The L4G6,
ut not L3A10, mAb speciﬁcally blocks TL1A-in-
memory cell phenotype. B6-wt mice were sensitized with 3  107
cells. Peripheral blood leukocytes gated on CD8H60 cells were
]) and expression of CD44 and Ly 6C. B, Resistance to MiHA-
ning anti-BALB.B memory cells were irradiated with 9.0 Gy of total
TCD BALB.B cells. Within 1 week after BMT, splenic CFU–IL-3
IL-3, where control is CFU numbers in B6naive recipients.press a
 107
in [PE
contai
 107uced cytotoxicity against DR3-transfected EL-4 tar-
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5et cells (Figure 5C). The ability of L4G6 mAb to
lock TL1A in vivo was demonstrated in a murine
sthma model in which intraperitoneal injection of
4G6 mAb signiﬁcantly reduced cytokine production
nd disease outcome in ovalbumin-immunized mice
Fang et al., manuscript under review, 2005, Univer-
ity of Miami School of Medicine, Department of
icrobiology and Immunology).
As administered in transplantations described pre-
iously, 250 g of anti-TWEAK and anti-TRAIL
Abs together with this anti-TL1A mAb were in-
ected into recipient mice intraperitoneally on day 0
nd 1 after transplantation. Naive B6-cdd recipients
hat received all 3 mAbs had a signiﬁcant number of
oth CFU–IL-3 and CFU-HPP colonies 5 days after
ransplantation of C3H.SW TCD BM, thus indicat-
ng that these mAbs did not interfere with early pro-
enitor cell presence and emphasizing the require-
ent for priming host T cells in this model (data not
hown). A high colony number was also observed in
ecipients primed to donor antigens that received syn-
eneic marrow (Figure 5A and B). In contrast, B6-cdd
ecipients primed to C3H.SW before transplantation
isplayed few colonies. As anticipated from earlier
esults (Figure 4), there was no diminution of resis-
ance in the presence of anti-TWEAK and anti-
RAIL mAbs together with nonblocking control
L3A10) anti-TL1A mAbs (Figure 5A and B). The
dministration of L4G6-inhibitory anti-TL1A mAb
lso did not result in augmentation of day 5 CFU
evels (Figure 5A and B). Therefore, intact resistance
nder these conditions supports the notion that 4 DR
athways are not critical for perforin-independent BM
igure 3. B6 cytotoxically normal and deﬁcient (perforin/FasL) rec
o donor CFU–IL-3 and CFU-HPP 48 hours after transplantati
nderwent transplantation with 1  107 TCD BM cells from MiH
ensitized to donor antigens 1 month before transplantation. Forty-
ssayed for the presence of CFU-granulocyte macrophage (CFU-GM
tatistical differences between groups were determined by analysisllograft rejection in this transplantation model. r
82ISCUSSION
In both murine and clinical transplantations, the
resence of anti-donor cytotoxic T lymphocytes
CTLs) has been associated with rejection of allo-
eneic progenitor cell grafts [25,26]. The transfer of
TL effector populations has also conferred resis-
ance against allogeneic BM [27]; however, it re-
ains to be demonstrated that CTL populations are
n absolute requirement for rejection of such grafts
nd/or that non-CTL populations are also involved.
oreover, the precise molecular mechanisms in-
olved in effecting resistance (cytotoxic noncyto-
oxic) remain to be established. T cell–mediated
ytotoxicity in vitro is entirely dependent on per-
orin and FasL [28]. It is interesting to note that the
xpression of several other TNF family members
ie, TRAIL, TWEAK, TL1A, and TNF) capable of
nducing apoptosis has been reported on T cells.
hese proteins could therefore potentially contrib-
te to the cytotoxic events in vivo—particularly in
onditions when cytokines may regulate expression
f such molecules after conditioning and progenitor
ell transplantation [29-33]. This study extends pre-
ious observations from our laboratory and others
oncerning resistance to marrow allografts in the
bsence of perforin and FasL by comparing their
arly T-cell responses with that in B6-wt mice and
xamining resistance while simultaneously inhibit-
ng these additional cytotoxic ligands. The ﬁndings
ndicate that a CD8 T cell–mediated effector mo-
ality independent of perforin and the TNF family
igands FasL, TRAIL, TWEAK, and TL1A can
sensitized to allogeneic MiHA exhibit indistinguishable resistance
er 9.0 Gy of total body irradiation, B6-wt or B6-cdd recipients
matched C3H.SW donors. Recipients were either unsensitized or
ours after transplantation, recipient splenocytes were harvested and
r CFU-HPP (B). Data represent CFUs per spleen (mean SEM).
ance with the Tukey multiple comparison test.ipients
on. Aft
A-mis
eight h
) (A) oapidly mediate resistance against allogeneic hema-
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Bopoietic stem/progenitor grafts in recipients sensi-
ized against donor MiHA allogeneic antigens.
We have previously observed that mice sensitized
o donor antigens can reject large numbers (1  107)
f transplanted marrow cells despite the inability to
ediate perforin- and FasL-dependent cytotoxicity
9,10]. These studies examined T cell–mediated resis-
ance after MHC-matched/MiHA-mismatched trans-
lantations as well as MHC-mismatched transplanta-
ions as early as 5 days after BMT by examining donor
rogenitor cell presence/absence in recipients. Recent
tudies have identiﬁed anti-MHC antibodies in the
erum of BMT recipients previously sensitized to
HC-disparate donors and suggest that such anti-
odies can be responsible for rapid marrow allograft
ejection (P. Taylor and B. Blazar, unpublished data,
005, University of Minnesota Cancer Center, De-
artment of Pediatrics). Antibodies to human MiHA
eg, HY encoded) have been reported in individuals
fter allogeneic stem cell transplantation [34,35]. We
id not detect antibodies against MiHA in B6 recipi-
nts sensitized (1 or 2 times) against donor C3H.SW
r BALB.B MiHA (data not shown). Together with
ur previous adoptive transfer ﬁndings and the
resent depletion studies with anti-CD8 mAb, host
D8 T cells have been demonstrated to be responsi-
le for the resistance against MiHA-disparate allo-
rafts in sensitized recipients [9,10].
Antigen-speciﬁc CD8 TM would be predicted to
ave been generated in such recipients, and we exam-
ned the presence of such a population in B6 mice
ensitized to BALB.B antigens before transplantation.
igure 4. A and B, B6-cdd mice sensitized to donor C3H.SW all
llogeneic MHC-matched/MiHA-disparate donors (C3H.SW) or
MT, recipients received no antibody, 250 g of anti-TRAIL, or 2
fter transplantation, recipient spleens were harvested and cultured
umber of CFUs (mean  SD; n  3-4 per group). C, 2PK3/mTR
t varying effector-target ratios for 4 hours. Anti-TRAIL 10 g/m
epresent mean speciﬁc lysis from triplicate cultures.y using a tetramer speciﬁc for B6 T-cell receptors a
B&MTgainst the immunodominant H60 MiHA encoded in
ALB background mice, B6 CD8 TM cells were iden-
iﬁed. Notably, we observed a pattern of resistance
fter immunodominant antigen responses in the rejec-
ion of MiHA-mismatched marrow allografts (Kom-
tsu and Levy, personal communication, 2001, Uni-
ersity of Miami School of Medicine, Department of
icrobiology and Immunology). An important obser-
ation in this study was the ﬁnding that rapid resis-
ance assessed by the presence/absence of donor pro-
enitor cells (ie, within 48 hours) was detected in both
ytotoxically normal and perforin and FasL cytotoxi-
ally deﬁcient recipients. The presence of TM in sen-
itized mice is consistent with the rapid and efﬁcient
esistance detected. More signiﬁcantly, these ﬁndings
upport the notion that CD8 TM can effect such
esponses by using effector modalities independent of
he 2 major pathways of cell-mediated cytotoxicity
10]. We interpret the results to indicate either that
he same effector pathways are being used in both
ytotoxically normal and cytotoxically deﬁcient mice
o mediate resistance or that different pathways with
irtually identical kinetics are being used in these 2
roups of recipient mice. In either case, the ﬁndings
emonstrate that CD8 TM can mediate potent resis-
ance against allogeneic progenitor cell populations
hrough a mechanism that does not include the major
ytolytic perforin/granzyme- and FasL-mediated
athways. It should be noted that the studies to date
o not rule out noncytotoxic effector mechanisms. T
nd NK cells can elaborate multiple cytokines, includ-
ng interferon 	, transforming growth factor 
, IL-12,
ns underwent transplantation with 1  107 TCD BM cells from
as a syngeneic control transplantation. On days 1 and 0 before
of both anti-TRAIL and anti-TWEAK blocking mAbs. On day 5
presence of CFU–IL-3 (A) or CFU-HPP (B). Data represent the
r 2PK3 L cells were incubated with 51Cr-labeled L929 target cells
n isotype control antibody (IgG2a) was added to each well. Dataoantige
B6-gfp
50 g
for the
AIL o
L or and TNF . Although all of these cytokines have been
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5hown to affect progenitor cell function and hemato-
oiesis, they have not been identiﬁed to date as effec-
or molecules in T or NK cell–mediated resistance
36-42]. Regardless of the pathways used by the effec-
or cells derived from cytotoxically impaired host
D8 TM, it may be worthwhile to consider that re-
istance in cytotoxically deﬁcient recipients in general
ould be potentially aided by diminished host cell
eath after total body irradiation conditioning and
ransplantation because of the absence of Fas-medi-
ted apoptosis in B6-cdd (but not B6-wt) recipients
43].
A recent study that examined NK-mediated resis-
ance in ablatively conditioned MHC-mismatched
osts noted that resistance assessed by splenic CFU-
ranulocyte macrophage 8 to 12 days after BMT did
ot necessarily correlate with rejection and subse-
uent donor chimerism [44]. We have previously re-
orted that donor chimerism could not be detected 14
ays after BMT in anti–donor-sensitized B6-cdd re-
ipients (ie, T cell–mediated resistance) after MiHA-
isparate marrow allografts [10]. One interpretation
f the NK resistance examined previously is that these
ells may be capable of effectively killing short-term
ut not long-term repopulating donor progenitor
ells, hence the subsequent appearance of donor chi-
erism in some surviving recipients [44]. The present
tudies concerning resistance found that the numbers
f splenic CFU–IL-3 and of the more primitive, ie,
ultipotential, CFU-HPP were both sharply dimin-
igure 5. A and B, B6-cdd mice were sensitized to donor alloantige
ells from allogeneic donors (C3H.SW) or B6-gfp as a syngeneic c
ntibody, 250 g of anti-TRAIL, 250 g of both anti-TRAIL a
nti-TL1A (L4G6) blocking mAbs. On day 5 after transplantation
FU–IL-3 (A) or CFU-HPP (B). Data represent the number of C
as tested against 51Cr-labeled EL4-DR3 and was shown to effect l
hen mixed with L4G6- and L3A10-containing supernatants in a 1
arget cells. Data represent mean speciﬁc lysis from triplicate cultushed. It will be interesting to determine whether the p
84otent T cell–mediated resistance studied here is ca-
able of eliminating both short-term and long-term
epopulating donor progenitor cell populations.
To extend our previous ﬁndings examining addi-
ional death ligand/receptor-signaling pathways that
ight contribute to the resistance observed in the
bsence of perforin and FasL, experiments in this
tudy examined for the ﬁrst time a potential contribu-
ion of the TL1A/DR3-mediated pathway. Expression
f TL1A has been reported on T-cell populations and
as been found to be upregulated in response to TNF
nd IL-1 on endothelial cell populations [13,29].
oreover, TL1A can reportedly act as a costimulatory
olecule to enhance T-helper type 1 activity, thus
esulting in augmented cytokine release that includes
nterferon  [13,29,32,33]. Accordingly, inhibition of
L1A/DR3 signaling could indirectly regulate mole-
ules that might affect T cell–mediated resistance to
llogeneic progenitor cell grafts. However, despite
imultaneously inhibiting TRAIL- and TWEAK-me-
iated killing to more sensitively monitor for an affect
f TL1A, resistance was not diminished in B6-cdd
ice sensitized against donor antigens that received
ransplants of MHC-matched BM. Therefore, under
ransplantation conditions in which 5 pathways capa-
le of mediating apoptosis are concurrently absent or
nhibited, resistance can be rapidly and effectively me-
iated. Accordingly, attempts to prevent rejection
linically directed toward inhibition of these cytolytic
athways may be ineffective, particularly if recipients
.SW) and then underwent transplantation with 1  107 TCD BM
. On days 1 and 0 before transplantation, recipients received no
i-TWEAK, or 250 g each of anti-TRAIL, anti-TWEAK, and
ient splenocytes were harvested and cultured for the presence of
ean  SD; n  3-4 per group). C, TL1A-containing supernatant
4-hour release assay. Varying amounts of TL1A supernatant were
me ratio and preincubated for 30 minutes before addition to thesens (C3H
ontrol
nd ant
, recip
FU s (m
ysis in a
:1 voluossess primed T cells speciﬁc for donor antigens.
h
c
t
T
f
f
e
a
S
i
t
u
r
p
h
g
l
a
p
t
t
w
r
a
r
i
a
t
a
i
t
A
t
a
w
v
e
(
o
g
R
H
R
1
1
1
1
1
1
1
1
1
1
2
Effector Cells Derived from Host CD8 Memory T Cells
BIt is interesting to note that several recent studies
ave reported the presence of circulating T cells spe-
iﬁc for HY and paternal (MiHA) alloantigens in mul-
iparous females many years after delivery [45,46].
hese ﬁndings suggest that signiﬁcant numbers of
emales could possess primed CD8 T cells speciﬁc
or HLA alloantigens, an observation that may help to
xplain the increased graft-versus-host disease–associ-
ted risk factor associated with female donors [47].
tudies have also reported that viral infections, includ-
ng cytomegalovirus and lymphocytic choriomeningi-
is virus, activate T cells that include alloreactive pop-
lations, some of which may affect graft-rejection
esponses [48]. Thus, the number of individuals who
ossess alloreactive TM, including those who receive
ematopoietic transplants, may be signiﬁcantly
reater than initially appreciated.
In summary, our ﬁndings may be interpreted in at
east 2 ways. First, resistance in recipients sensitized
gainst donor antigens may be a result of a non–
erforin/FasL-mediated cytotoxic effector pathway
hat is presently undeﬁned. Alternatively or in addi-
ion, the involvement of noncytotoxic resistance path-
ays—for example, mechanisms that block the matu-
ation or differentiation of progenitor cells—could
lso be important [49]. Understanding the pathways of
esistance mediated by effector cells derived from na-
ve T cells and TM after both ablative and nonmyelo-
blative conditioning regimens will be important for
he development of effective strategies for support of
llogeneic progenitor cell engraftment and tolerance
nduction after hematopoietic stem cell transplanta-
ion.
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